Introduction: By means of liquid-liquid extraction with ethyl acetate, a rapid,
Methods:
The method was verified and successfully applied to evaluate the pharmacokinetics of ponatinib in Sprague-Dawley rats.
Results: Ponatinib showed dose-dependent exposure in the circulation system, and the absolute bioavailabilities of ponatinib were 43.95 ± 2.40%, 47.69 ± 5.08% and 55.02 ± 2.50% after intragastric administration of 7.5, 15.0 and 30.0 mg/kg ponatinib in rats, respectively. After consecutive administration at 3.75 mg/kg for 7 days, there was distinct accumulation of ponatinib (AUC 0-? = 5479.41 ± 757.07 lg h/L) relative to that of a single dose (AUC 0-? = 2301.84 ± 787.10 lg h/L, p\0.05), and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h (p\0.05). Analysis of ponatinib in various tissues revealed it was distributed widely in the body, highly exposed in the lung, thyroid, and lowly exposed in plasma, the brain, bone and the liver, indicating its potential action on lung cancer with lower system toxicity. Ponatinib was eliminated primarily in feces at 26.17 ± 7.70% of its original form and only 0.24 ± 0.10% in urine.
Conclusion:
For the first time, the pharmacokinetics of ponatinib were
INTRODUCTION
Tyrosine kinase inhibitors (TKIs) are used to target the BCR-ABL1 gene, which is a well-established and highly effective strategy for the management of chronic myeloid leukemia (CML) [1] . The fusion protein, encoded by the BCR-ABL1 gene, deregulates tyrosine kinase activity which is believed to play an important role in CML development [2] . Imatinib (IM), the first TKI, was designed to inhibit BCR-ABL1 kinase activity and was initially found to have significant activity in preclinical models [3] . Despite this initial success, unfortunately, it was clear that many CML patients developed resistance to IM in the short term, because of point mutations in BCR-ABL1 that reduce IM's ability to bind to its target [4, 5] . It suggested that resistant CML may still be dependent on BCR-ABL1 activity [6] . Indeed, the second generation of tyrosine kinase inhibitors were developed to overcome the first-generation IM resistance in many CML patients, such as nilotinib (NIL) and dasatinib (DAS); however, the first generation and second generation of TKIs (IM, DAS, and NIL) were denied access by the gatekeeper T315I mutation [7] . Therefore, ponatinib, the third-generation TKI, was developed to target BCR-ABL, including T315I mutation. Ponatinib (Fig. S1 ), approved by the US Food and Drug Administration (FDA) in 2013, is a novel kinase inhibitor designed to include a carbon-carbon triple bond that extends from the purine scaffold, with potent activity in clinical trials and cells with BCR-ABL1 mutations including T315I, which confers resistance to the approved and available BCR-ABL1 inhibitors IM, DAS, and NIL [8] .
Ponatinib inhibits BCR-ABL1 at concentrations above 40 nmol/L [9] , which are achieved with doses of 30 mg and greater, and shows promising clinical activity [10] . It is reported that ponatinib displays pH-dependent aqueous solubility in vitro, indicating a large decrease in solubility with increasing pH [11] . A previous study evaluated the pharmacokinetics and bioavailability of a single oral administration of ponatinib under fasting conditions and following consumption of high-and low-fat meals by healthy subjects. The results indicate that consumption of a high-or low-fat meal within 30 min prior to administration of ponatinib had no effect on the single-dose pharmacokinetics of ponatinib [12] . Moreover, studies in vitro found that ponatinib is a substrate of cytochrome P450 (CYP)3A4/5; therefore, caution should be exercised with the concurrent use of ponatinib and strong CYP3A4 inhibitors in clinical models [13] .
In this study, we have developed a sensitive, specific, and new LC-MS/MS method to study ponatinib. This method has never been applied to the study of ponatinib and was successfully applied to the pharmacokinetic study in rats.
METHODS

Reagents and Chemicals
Ponatinib (purity[97%) was provided by SANHOME 
Instrument and Chromatographic Conditions
An AB SCIEX API 4000 mass spectrometer was equipped with a Shimadzu HPLC system (LC-20A), the US AB MS system (API4000), electrospray ionization, and an Analyst 1. The source parameters were set as follows: spray voltage (IS) 5500 V, the auxiliary gas 1 (GS 1, N2) 50 Arb, auxiliary gas 2 (GS 2, N2) 55 Arb, auxiliary heating gas temperature (TEM) 580°C, air curtain gas (CUR) 30 Arb, collision gas (CAD, 
Sample Preparation
The biological matrices samples (plasma, tissue homogenates, urine, fecal homogenates) were extracted using a liquid-liquid extraction technique. 50 lL of plasma, tissue and excretion sample was spiked with 5 lL of IS solution (0.5 lg/mL) and mixed; 0.5 mL of ethyl acetate was added and the mixture was vortexed for 3 min, followed by centrifugation at 3310g for 5 min (Thermo Sovall Biofuge Stratos, Germany). 400 lL of supernatant of the upper organic layer was transferred to another Eppendorf tube and evaporated to dryness in a rotary evaporator (SPD2010, Thermo Fisher Scientific, NJ, USA) at 45°C.
The residue was reconstituted in 200 lL of methanol and centrifuged at 30,065g for 5 min (Thermo Sovall Biofuge Stratos, Germany) and 5.0 lL of aliquot was injected for analysis [15] .
Method Validation
The method was validated in terms of specificity, recovery, matrix effect, linearity, accuracy, precision and stability according to the FDA guidelines for validation of bioanalytical methods.
Specificity
The specificity was assessed by analyzing six different batches of blank rat matrices with and without ponatinib and IS by comparison of corresponding peaks to exclude potential endogenous interference. All the plasma samples were pretreated and analyzed under the same procedure as described above.
Recovery and Matrix Effect
The recovery for ponatinib and matrix effect from rat biological matrices extract were determined at 2, 50 and 1000 ng/mL (n = 5) in plasma, while 10, 100 and 1000 ng/mL (n = 5) in urine and feces by comparing 3 sets of samples: (A) ponatinib spiked into biological matrices before extraction but IS spiked into dry residue; (B) both ponatinib and IS spiked into the residue after extraction of blank biological matrices; and (C) both ponatinib and IS spiked into the residue after extraction of ultrapure water. Recovery was calculated as the percentage of the peak area ratio (ponatinib/ IS) of set A compared to that of set B. Similarly, the matrix effect was calculated as the percentage of the peak area ratio (ponatinib/ IS) of set B compared to that of set C.
Linearity
Calibration standards were prepared by spiking 5 lL of working solutions into 45 lL of drug-free rat plasma to achieve final concentrations of 1, 2, 5, 10, 20, 50, 100, 200, 500 and 1000 ng/mL; the same procedure was applied to urine and feces to range from 5 to 1000 ng/mL. 
Accuracy and Precision
Previous studies had shown that ponatinib has distinct toxicity. The mortality of rats increased when ponatinib was repeatedly given intragastrically over 6 mg/kg in rats. We chose an intragastric multi-dose administration of 3.75 mg/kg in this study. Two groups of SD rats (n = 6 per group, divided between male and female randomly) were used for multi-doses; one group was administrated 3.75 mg/kg of ponatinib for a single dose while the other group received consecutive administration for 
Tissue Distribution in Rats
Three groups of male and female rats (n = 6 per group) received a single dose of 15.0 mg/kg of ponatinib by i.g. administration. The rats were fasted overnight but with free access to water before the test. Heart, liver, brain, kidney, lung, thyroid, thymus, stomach, intestine, testis (male rats only), ovary (female rats only), bone, spleen and pancreas samples were collected at designated times (3, 9, 24 h) after administration of 15.0 mg/kg of ponatinib in a sodium citrate buffer solution of pH 2.75. 0.2 g of the total amount of all rat tissues (except bone) were cut into pieces and combined with 2.0 mL of ultrapure water; with a high-speed tissue pulverizer, they were fully homogenized into 0.1 g/mL of tissue homogenates [17] . However, because the sample amounts of the thymus, testis, ovary are insufficient, the final concentration of them was expressed in term of their homogenate, respectively. For sufficient extraction of ponatinib, the crushed femur and right legs of rats were soaked overnight with 1 mL extraction solvent (methanol:water = 50:50, v/v), and the supernatant was prepared.
Excretion of Ponatinib in Rats
Six Sprague-Dawley rats (randomly divided between male and female) were fasted overnight but with free access to water before the test. Urine and feces were collected using a metabolic cage 12 h before and 12, 24, 48, 72, 96, 120, 144 h after intragastric administration of ponatinib in sodium citrate buffer solutionof pH 2.75 at 15.0 mg/kg. Rat feces were weighed and diluted with ultrapure water (5 mL/g), and then fully homogenized into a suspension of 0.2 g/mL.
Compliance with Ethics Guidelines
Animal care was in accordance with the Guidelines for Animal Experimentation of China Pharmaceutical University (Nanjing, China) and the protocol was approved by the Animal Ethics Committee of the Institution. All institutional and national guidelines for the care and use of laboratory animals were followed.
RESULTS
Specificity and Matrix Effect
Ethyl acetate was chosen as the solvent for liquid-liquid extraction, and it showed fairly good recovery and reproducibility. The specificity of the analysis was assessed in plasma, urine, feces and various tissues.
Typical chromatograms of blank bio-samples, a blank bio-sample spiked with ponatinib and warfarin (IS), and the sample after ponatinib administration are shown in Fig. S2-S4, respectively. The retention time for ponatinib and warfarin (IS) remained stable at 3.8 and 4.0 min, respectively. No distinct interference was found, and the matrix effect of ponatinib was 85.9 * 103.3%.
Linearity
Over a concentration between 1 and 1000 ng/ mL in plasma, the ratio of ponatinib and (Table S1 ).
Recovery and Precision
Based on the method developed, we achieved an acceptable recovery of around 60% in plasma at low, medium and high concentrations, yet over 80% in urine and feces (Table S2 ).
The intra-batch precision in rat plasma was less than 8%, and the accuracy was -4.55 * 9.24%. The RSD (%) and RE (%) of the inter-batch in different biological matrix (plasma/urine/feces) were all below 7% and 10%, respectively, except the RE (%) at the lowest concentration in feces (Table S3 ). The intra-and inter-batch variations, as well as the accuracy, were within the acceptable range, except that at the lowest concentration in feces.
Stability
The stability of ponatinib under various storage conditions is shown in Table S4 . All of the RE (%) and RSD (%) values were below 15%, indicating that ponatinib was stable.
Pharmacokinetics, Tissue Distribution, Excretion Study
Pharmacokinetics After intragastric administration at 7.5, 15.0, 30.0 mg/kg, ponatinib showed dose-dependent exposure in plasma (Fig. 1) . Based on the parameters and plasma concentration-time curve, the area under the curve (AUC) and C max positively increased along with the elevation of dosages, and the absolute bioavailabilities of ponatinib were 43.95 ± 2.40%, 47.69 ± 5.08%, 55.02 ± 2.50% in rats, respectively ( Table 1 ). The C max and AUC increased positively along with the elevation of dosages. There appeared a distinct absorption phase before T max at around 8 h, and thereafter, the plasma concentration gradually decreased in the elimination phase, with a half-life around 10 h (Table 1) . After intravenous injection at 3.0 mg/kg, the level of value of 280.64 ± 129.27 lg/L and the elimination half-life of 6.17 ± 0.95 h, significantly lower than those of intragastric administration of ponatinib at higher doses (Table 1) .
Considering the toxicity of ponatinib, a lower dose (3.75 mg/kg) was chosen in the PK study of multiple dosages. Based on the parameters (Table 2) and plasma concentration-time curve (Fig. 2) 
Tissue Distribution
Tissue analysis revealed that the highest levels of ponatinib were observed in the lung and thyroid, while there was rather low exposure of ponatinib in bone and the brain (Fig. 3) .
Excretion of Ponatinib in Rats
The amount of ponatinib in urine and feces was determined after intragastric administration of ponatinib in a sodium citrate buffer solution of pH 2.75 at 15.0 mg/ kg. As shown in Fig. S5 and Table 3 , the total excretion ratios of ponatinib within 144 h in urine and feces were 0.24 ± 0.10% and 26.17 ± 7.70%, respectively.
DISCUSSION
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI), which is effective for the resistant gatekeeper of T315I mutation. Although previous study has evaluated the pharmacokinetics and bioavailability of a single oral dose of ponatinib in healthy subjects, tissue distribution, the pharmacokinetic properties after multiple doses in animals and the correlation between dosage and exposure level is not clear. In this study, a highly sensitive, reliable and specific LC-MS/MS method was developed and validated for the quantitative assay of ponatinib in biosamples of rats. To assess the exposure of ponatinib after 7 days of consecutive administration, the samples were collected at the exact same time points as that of a single dose. Because ponatinib was not absorbed quickly and the half-life is long (more than 10 h in rats), the sample points were set between 0.5 and 72 h based on our pilot experiments and a previous report [1] . Moreover, for a single-dose pharmacokinetic study of ponatinib, we had examined the 7.5, 15.0, 30.0 mg/kg based on an online report [18] .
However, for multiple-dose administration, consecutive doses of 15, 7.5, 6.0 were tested, and a lower dose of 3.75 mg/kg was finally used due to the strong toxicity and high mortality after repeated administration over 6 mg/kg in rats. Toxicity was displayed to some extent even at the dose of 3.75 mg/kg for a consecutive administration for 7 days. Ponatinib showed dose-dependent exposure in the plasma, with the absolute bio-availability around 50%. After consecutive administration at 3.75 mg/kg for 7 days, there was distinct accumulation of ponatinib relative to that of a single dose with the AUC increasing 2.4-fold, and the MRT increased from 16.77 ± 1.91 to 21.34 ± 1.27 h.
The increased exposure and longer MRT suggested the necessity of dosage adjustment clinically. In general, ponatinib was widely distributed into various tissues, and the plasma level of ponatinib was much lower than in most organs/tissues. Ponatinib was highly exposed in the lung and thyroid, while being lowly exposed in the brain, bone and liver. This property suggests that the lung is an optimal target organ for the use of ponatinib. On the other hand, the level of ponatinib was fairly low in the stomach, intestine and liver, although it was administrated intragastrically. The low exposure level of ponatinib in the brain, bone, stomach, intestine and liver suggested its low toxicity in corresponding tissues/organs and less side effects clinically. The excretion data showed that ponatinib was primarily excreted through the feces in the prototype drug form. Several limitations of this study should be acknowledged. The tissue distribution study showed that ponatinib was highly exposed in the lung, thyroid, and lowly exposed in plasma, the brain, bone and liver of rats, suggesting its potential action on lung cancer and low systemic toxicity. It does not necessarily indicate the similar properties in patients to the rats because there is distinct difference between rats and human, and between the normal tissue and malignant tumors of lung. We did not examine the metabolism of ponatinib in cancerous lung, it is possible that the elimination or metabolism of ponatinib alters in patients and malignant tumor, and the exposure of it will dramatically change.
Moreover, ponatinib showed dose-dependent exposure in the circulation system at three single doses of 7.5, 15.0, 30.0 mg/kg.
Considering the distinct toxicity, we applied a fairly low, consecutive administration at 3.75 mg/kg for 7 days. To our surprise, it showed significant accumulation of ponatinib 
